| Original language | English (US) |
|---|---|
| Pages (from-to) | 1335-1336 |
| Number of pages | 2 |
| Journal | Movement Disorders |
| Volume | 32 |
| Issue number | 9 |
| DOIs |
|
| State | Published - Sep 2017 |
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease : A randomized, double-blind, placebo-controlled multicenter study. / Goetz, Christopher G.; Stebbins, Glenn T.; Chung, Kathryn A. et al.
In: Movement Disorders, Vol. 32, No. 9, 09.2017, p. 1335-1336.Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease
T2 - A randomized, double-blind, placebo-controlled multicenter study
AU - Goetz, Christopher G.
AU - Stebbins, Glenn T.
AU - Chung, Kathryn A.
AU - Nicholas, Anthony P.
AU - Hauser, Robert A.
AU - Merkitch, Douglas
AU - Stacy, Mark A.
N1 - Funding Information: Academy for Continued Healthcare Learning, Outcomes Insights, Expert Connect, HealthLogix, Cowen and Company, Pharma Two B, Ltd, Pfizer, Inc., and RMEI Medical Education for Better Outcomes. D.M. reports a salary from Rush University Medical Center. M.A.S. reports consulting and advisory board membership with honoraria from Acadia, Best Doctors, Biotie, Osmotica, Pfizer, Revance, Saraepta Therapeutics, and Sunovion Pharmaceuticals; grants and research from the Michael J. Fox Foundation, the National Institutes of Health, Parkinson Study Group, and Pharma2B; royalties from Informa Press for Handbook of Dystonia; and a salary from Duke University Medical Center. Funding Information: *Corresponding author: Dr. Christopher G. Goetz, Suite 755, Rush University Medical Center, 1725 W. Harrison Street, Chicago, IL 60612; cgoetz@rush.edu Funding agency: This work was supported by a grant from the Michael J. Fox Foundation for Parkinson’s Research.
PY - 2017/9
Y1 - 2017/9
UR - http://www.scopus.com/inward/record.url?scp=85021348433&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021348433&partnerID=8YFLogxK
U2 - 10.1002/mds.27092
DO - 10.1002/mds.27092
M3 - Comment/debate
C2 - 28646494
AN - SCOPUS:85021348433
VL - 32
SP - 1335
EP - 1336
JO - Movement Disorders
JF - Movement Disorders
SN - 0885-3185
IS - 9
ER -